APLS
Price
$19.44
Change
-$0.09 (-0.46%)
Updated
Jul 11 closing price
Capitalization
2.44B
30 days until earnings call
CYTK
Price
$37.01
Change
+$0.42 (+1.15%)
Updated
Jul 11 closing price
Capitalization
4.42B
19 days until earnings call
Interact to see
Advertisement

APLS vs CYTK

Header iconAPLS vs CYTK Comparison
Open Charts APLS vs CYTKBanner chart's image
Apellis Pharmaceuticals
Price$19.44
Change-$0.09 (-0.46%)
Volume$1.56M
Capitalization2.44B
Cytokinetics
Price$37.01
Change+$0.42 (+1.15%)
Volume$960.69K
Capitalization4.42B
APLS vs CYTK Comparison Chart in %
Loading...
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APLS vs. CYTK commentary
Jul 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a StrongBuy and CYTK is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 13, 2025
Stock price -- (APLS: $19.44 vs. CYTK: $37.01)
Brand notoriety: APLS and CYTK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 65% vs. CYTK: 59%
Market capitalization -- APLS: $2.44B vs. CYTK: $4.42B
APLS [@Biotechnology] is valued at $2.44B. CYTK’s [@Biotechnology] market capitalization is $4.42B. The market cap for tickers in the [@Biotechnology] industry ranges from $318.23B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whileCYTK’s FA Score has 1 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • CYTK’s FA Score: 1 green, 4 red.
According to our system of comparison, CYTK is a better buy in the long-term than APLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 5 TA indicator(s) are bullish while CYTK’s TA Score has 5 bullish TA indicator(s).

  • APLS’s TA Score: 5 bullish, 4 bearish.
  • CYTK’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both APLS and CYTK are a good buy in the short-term.

Price Growth

APLS (@Biotechnology) experienced а +6.46% price change this week, while CYTK (@Biotechnology) price change was +6.78% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.14%. For the same industry, the average monthly price growth was +16.46%, and the average quarterly price growth was +20.75%.

Reported Earning Dates

APLS is expected to report earnings on Nov 10, 2025.

CYTK is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+9.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($4.42B) has a higher market cap than APLS($2.44B). CYTK YTD gains are higher at: -21.322 vs. APLS (-39.079). APLS has higher annual earnings (EBITDA): -176.08M vs. CYTK (-513.62M). CYTK has more cash in the bank: 938M vs. APLS (358M). APLS has less debt than CYTK: APLS (470M) vs CYTK (791M). APLS has higher revenues than CYTK: APLS (776M) vs CYTK (19.2M).
APLSCYTKAPLS / CYTK
Capitalization2.44B4.42B55%
EBITDA-176.08M-513.62M34%
Gain YTD-39.079-21.322183%
P/E RatioN/AN/A-
Revenue776M19.2M4,042%
Total Cash358M938M38%
Total Debt470M791M59%
FUNDAMENTALS RATINGS
APLS vs CYTK: Fundamental Ratings
APLS
CYTK
OUTLOOK RATING
1..100
617
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
10081
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
6463
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APLS's Valuation (71) in the Medical Distributors industry is in the same range as CYTK (100) in the Biotechnology industry. This means that APLS’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (81) in the Biotechnology industry is in the same range as APLS (100) in the Medical Distributors industry. This means that CYTK’s stock grew similarly to APLS’s over the last 12 months.

APLS's SMR Rating (98) in the Medical Distributors industry is in the same range as CYTK (100) in the Biotechnology industry. This means that APLS’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Price Growth Rating (63) in the Biotechnology industry is in the same range as APLS (64) in the Medical Distributors industry. This means that CYTK’s stock grew similarly to APLS’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for APLS (100) in the Medical Distributors industry. This means that CYTK’s stock grew significantly faster than APLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSCYTK
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
75%
MACD
ODDS (%)
Bullish Trend 2 days ago
75%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
Bearish Trend 13 days ago
79%
Bearish Trend 13 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VRLCX19.47N/A
N/A
Voya Large Cap Growth Port R6
POVYX31.37N/A
N/A
Putnam International Equity Y
EMAYX17.81N/A
N/A
Gabelli Entpr Mergers & Acquisitions Y
GCPAX20.38N/A
N/A
Gateway Equity Call Premium A
MLINX9.90-0.04
-0.40%
NYLI Winslow Large Cap Growth Inv Class

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with ROIV. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
-0.46%
ROIV - APLS
48%
Loosely correlated
-1.82%
DNLI - APLS
46%
Loosely correlated
-5.41%
EYPT - APLS
45%
Loosely correlated
-5.47%
BPMC - APLS
44%
Loosely correlated
-0.02%
DAWN - APLS
44%
Loosely correlated
-5.56%
More

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with IDYA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
+1.15%
IDYA - CYTK
50%
Loosely correlated
-1.40%
IMVT - CYTK
49%
Loosely correlated
+3.60%
KRYS - CYTK
48%
Loosely correlated
-1.05%
BEAM - CYTK
46%
Loosely correlated
-3.95%
ROIV - CYTK
44%
Loosely correlated
-1.82%
More